To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Read time: Less than a minute
Evotec AG has announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim. The collaboration, which was initiated in August 2004, has up to now resulted in seven milestone payments.
The achievement of the current milestone has led to a payment to Evotec of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for Pre-Development studies in a cardiometabolic program.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are extremely pleased that we have achieved another milestone in our alliance with Boehringer Ingelheim. This is the second milestone that we have achieved in 2009 and further demonstrates the success of our collaboration. We are looking forward to continuing our collaboration into 2010 and beyond and achieving further milestones as we progress several projects towards the clinic.”
The achievement of the current milestone has led to a payment to Evotec of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for Pre-Development studies in a cardiometabolic program.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are extremely pleased that we have achieved another milestone in our alliance with Boehringer Ingelheim. This is the second milestone that we have achieved in 2009 and further demonstrates the success of our collaboration. We are looking forward to continuing our collaboration into 2010 and beyond and achieving further milestones as we progress several projects towards the clinic.”
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
